76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
S Senseonics Holdings Inc
S
Open
0.54 1.89
Overview
Share price change
24h
Min
0.52
Max
0.54
Income | 1.2M -14M |
|---|---|
Sales | -2M 6.3M |
EPS | -0.02 |
Profit margin | -227.889 |
Employees | 117 |
EBITDA | -949K -13M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +192.45% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | -65M 400M |
|---|---|
Previous open | -1.35 |
Previous close | 0.54 |
Senseonics Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Senseonics Holdings Inc Forecast
Price Target
By TipRanks
192.45% upside
12 Months Forecast
Average 1.55 USD 192.45%
High 2 USD
Low 1.1 USD
Based on 2 Wall Street analysts offering 12 month price targets forSenseonics Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Senseonics Holdings Inc
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
